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First isolated in 2009 from the ear canal of a Japanese patient, Candida auris has 
become a growing concern. It has been found to have a similar profile of virulence 
to Candida albicans. It forms biofilms and produces phospholipase and protease 
activity. The virulence of C. auris varies according to the strain, with aggregating 
strains showing less virulence than non-aggregating strains, though reports find 
it to be less virulent overall than C. albicans. Alarmingly, however, it has shown 
greater resistance to multiple drugs from all three classes of antifungals and 
routine cleaning protocols. Most at risk of invasive and systemic infections are 
severely immunocompromised patients in intensive care settings particularly 
those with a urinary catheter in situ. Due to impaired immunity and associated 
comorbidities, patients with diabetes mellitus are considered a high-risk group. 
The study investigated whether synthetic urine mimicking the high glucose and 
low pH conditions found in diabetic urine would increase the production of 
biofilms, protease and phospholipase of an aggregating (NCPF 8977) and non-
aggregating strain (NCPF 8971) of C. auris. C. auris was found to grow well in 
the synthetic urine media in its planktonic form where the culture medium is 
shaken to preventing biofilm formation, and the growth increased in line with 
glucose concentration and varied in respect to pH with pH 5.6 showing less 
growth than pH 5.2 or pH 6.3. The study found that there was no significant 
change in biofilm formation at any of the tested pH levels and glucose 
concentrations. However, variation in phospholipase and protease activity was 
seen when the conditions were altered, and this appeared to be in a strain 
dependent manner. Other studies have shown that C. auris produces protease 
iv 
 
and phospholipase in a strain dependent manner, though this study has shown 
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This MSc (by research), entitled “Determination of the role of glucose and pH in 
the production of biofilms, phospholipase and protease in Candida auris” aims to 
determine whether there is increased virulent activity in two strains of the fungal 
pathogen C. auris in synthetic urine supplemented with increasing glucose 
concentrations and varying pH levels. Biofilm formation, phospholipase and 
protease are recognised virulence factors, which aid the in vivo spread and 
colonisation of the organism. Here we will determine whether synthetic urine 
mimicking the raised glucose and low pH as seen in diabetes mellitus would 
increase the virulence of two strains of Candida auris.  
 
1.2 Diabetes mellitus 
1.2.1 Brief summary 
According to Zaccardi et al (2015), diabetes mellitus (DM), more commonly 
referred to simply as diabetes, is a group of diseases that occur as a result of 
impaired insulin production or impaired insulin sensitivity. Mayer1 et al (2007) 
describe insulin as a 51-residue protein consisting of two chains, an A chain and 
a B chain, connected by disulphide bonds. It is produced in β-cells in the Islets of 
Langerhans in the pancreas and its main roles are to stimulate the absorption of 
glucose and to suppress hepatic gluconeogenesis. Gluconeogenesis is largely 
performed in the liver and is a method of glucose regulation whereby glycogen 
stored in the liver is converted to glucose during periods of fast when systemic 
glucose levels are depleted. This process is regulated by insulin to maintain blood 
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glucose levels (Hatting et al., 2017). DM includes type I (DMI) which usually has 
its onset in childhood and is characterised by the failure of the pancreas to 
produce insulin or to produce it in sufficient quantities leading to insulin deficiency. 
Type II DM (DMII) usually has its onset in adulthood and occurs generally as a 
result of obesity, a high fat and sugar diet, and lack of exercise. DMII typically 
involves a resistance or reduced sensitivity to insulin. Gestational diabetes is a 
form of DM that occurs in pregnancy and is usually resolved following delivery of 
the baby. The insulin resistance or deficiency seen in DM leads to poor regulation 
of gluconeogenesis and raised blood glucose levels (hyperglycemia) (Zaccardi et 
al., 2015) above the normal fasting blood glucose of around 0.6 – 1.0 mg/mL 
(Güemes et al., 2015). Long-term hyperglycemia can have implications for health 
and can lead coronary heart, cerebrovascular, nephropathy, retinopathy and 
neuropathy complications. Prolonged high blood glucose levels can lead to the 
excretion of glucose into the urine, this process is regulated by the kidneys (Lofty 
et al., 2016). The kidneys are two bean shaped organs situated in the left and 
right retroperitoneal space. The kidney is highly vascularised and receives 
around 25% of cardiac output. It participates in the removal of toxins and balance 
of fluid and constituents of blood entering the kidney via the renal arteries and 
exiting via the renal veins. The nephron, of which there are around 1 million, is 
the functional unit of the kidney and is formed of a filtering unit called the 
glomerulus, which filters water and small solutes from plasma, and a tubular 
region made up of the proximal tubule, the loop of Henle, and the distal tubule 
which are responsible for the reabsorption of electrolytes, amino acids, proteins 
and glucose, any remaining water and solutes are excreted as urine (Hoenig & 
Zeidel., 2014). In a healthy person, the glomeruli filter around 180 g of glucose 
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from plasma each day and virtually all of this glucose is reabsorbed. The 
reabsorption is mediated by sodium-glucose linked transporter (SGLT) proteins 
present in the cell membrane of the proximal tubule and a healthy individual will 
have a zero-net excretion of glucose in the urine. The transporter proteins are 
only able to reabsorb approximately 375 mg glucose/min and when the blood 
glucose level exceeds 1.6-1.8 mg/mL and once the threshold for reabsorption is 
exceeded, the excess glucose is excreted in the urine (glucosuria) as seen in DM 
(Zaccardi et al., 2015). 
1.2.2 Urinary infections in diabetes 
Patients with DM are at an increased risk of urinary tract infections. The reason 
for the increased risk is largely unknown though it is proposed that glucosuria, 
impaired immune response and leukocyte function are amongst the possible risk 
factors (Nicolle., 2014). Tandogdu and Wagenlehner (2016) consider DM a 
primary risk of UTIs alongside age, previous history of UTI and sexual activity. 
UTIs are more common in women, though age increases the risk of UTI in men. 
DM is associated with comorbidities and according to the Public Health England 
(PHE) (2018), DM is the largest single cause of end-stage renal failure and 
excluding accidents, the greatest cause of lower limb amputations, in addition to 
higher rates of cardiac disease, foot ulcers and nerve damage. McAllister et al 
(2014) found that patients with high blood glucose levels of >11.1 mmol/L 
admitted to Intensive Care Units (ICU) for cardiovascular and respiratory 
diseases had prolonged hospital stays, poorer prognoses and higher rates of 
mortality than those with a blood glucose level of <6.1 mmol/L. According to the 
Health Innovation Network (2016), 56% of UTIs are associated with indwelling 
urinary catheters. Shackley et al (2017) report that catherization rates across the 
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UK vary amongst hospital sites and range between 12-26%, though the highest 
catheterisation rates are seen ICU settings where over 70% of patients have an 
in situ indwelling urinary catheter. Catheterisation is more prevalent in males than 
females is more common in patients aged >70 in a hospital setting. The rationale 
for catheterisation varies and detailed statistics are unavailable, though Shackley 
et al (2014) offers an explanation for gender variation and suggests that males 
are catheterised more than females due to their susceptibility to prostate 
disease and the increased likelihood of urinary retention following surgery. 
However, the presence of a urinary catheter increases the risk of a catheter 
associated UTI (CAUTI). Maxwell et al (2014) states that each day a catheter is 
left in situ increases the risk of CAUTI by 5%. In-dwelling medical devices such 
as urinary catheters are associated with biofilm formation and have been widely 
studied in relation to Candida albicans. Reports vary, though the use of urinary 
catheters is implicated in over 60% of cases of infection with C. auris (Snyder & 
Wright., 2019).  To date, there is little evidence to determine if C. auris is 
associated with increased risk of infection with respect to increasing 
concentrations of urine glucose.  
1.3 Structure of a typical yeast cell 
Yeasts are unicellular eukaryotic organisms and they contain almost the same 
organelles as those found in more complex eukaryotic organisms which include 
endoplasmic reticulum, Golgi apparatus, mitochondria, cytoplasm, ribosomes, 
cytoskeleton etc. Yeast cells also have a cell wall. The cell wall is mostly 
comprised of polysaccharides, proteins and lipids, and provides the cell with 
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rigidity and structure and protection from shearing forces. The cell wall plays a 
role in the adhesion of the cell to surfaces and in pathogenesis (Murray., 2016).  
1.4 Candida auris 
Candida auris, is a newly emerging yeast pathogen which was first identified in 
2009 in the ear canal of a Japanese. It can colonise the skin and mucosa and 
lead to invasive and systemic infections in immunocompromised patients (Satoh 
et al., 2009). The Center for Disease Control (CDC) (2018), the World Health 
Organisation (WHO) (2018), PHE (20171) and many other health organisations 
all consider C. auris to be an emerging concern as it has shown resistance to 
multiple drugs from all three classes of antifungal drugs used in Candida spp. and 
to standard cleaning regimens (Ku et al., 2018). 
1.4.1 Antifungal drugs 
Antifungal drugs are grouped into three main classes based on their site of action: 
azoles, polyenes and echinocandins. Azoles, such as clotrimazole and 
miconazole, inhibit the synthesis of ergosterol, a vital component in fungal cellular 
membranes. Polyenes, which include amphotericin B and nystatin, disrupt the 
formation of fungal cell membranes by binding to ergosterol. Echinocandins like 
capsofungin and micafungin inhibit the synthesis of (1,3)-beta-d-glucan synthase, 
a vital cell wall component of many fungi. Allylamines are another class of 
antifungal drugs which also target sterol synthesis, though they are not used in 
the treatment of Candida infections (Owens et al., 2010).  
According to the CDC, around 90% of C. auris isolates were found to show 
resistance to fluconazole, about 30% are resistant to amphotericin B and <5% 




Analysis of the C. auris genome by Rossato and Colombo (2018) has revealed 
many uncharacterised proteins, though it has been shown to be closely related 
to four other Candida species: Candida heamulonii, Candida duobushaemulonii, 
Candida pseudohaemulonii and Candida lusitaniae. Around 40% of C. auris 
proteins are orthologus to those of C. lusitaniae which also has limited 
susceptibility to amphotericin B. C. haemulonii also has limited susceptibility to 
amphotericin B and azoles. The CDC (2019) also report that isolates have shown 
a mutation in the Erg11 gene responsible for encoding the azole target enzyme 
14-demethylase (Erg11p), which suggests that C. auris would be unlikely to 
respond to fluconazole. Erg11 mutations have long been associated with azole 
resistance in C. albicans (Xiang et al., 2013). The C. auris genome demonstrates 
genes well-characterised in the role of biofilm formations, the production of 
proteases, phospholipases and transporter proteins which likely contribute to its 
azole resistance as well as to its virulence (Cortegiani et al., 2018).  
1.4.2 Epidemiology of Candida auris 
There have been multiple confirmed cases of C. auris reported throughout the 
world including over 1500 cases in South Africa (Govender et al., 2018). By 
October 2018, there had been 433 confirmed cases in the United States of 
America with a further 30 probable cases (CDC, 2018). In April 2018, the 
European Centre for Disease Prevention and Control (ECDC) published the 
Rapid Risk Assessment, until that time there had been 620 reported cases of 
infection or colonisation throughout Europe. Of these, 221 incidences were 
reported in the UK at 35 hospital sites in patients who had been transferred from 
3 hospitals where the largest outbreaks were seen. Most of the cases of infection 
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or colonisation were detected through screening of swabs and samples taken 
from commonly colonised areas of the skin and mucosa. Approximately a quarter 
of the positives screens led to a clinical infection with 27 patients developing 
blood stream infections (candidaemia). In July 2017, PHE launched a pilot survey 
at 5 hospital sites to screen patients admitted to intensive care units to determine 
the origin of colonisation with C. auris and inform future surveillance (PHE., 
20172). It is acknowledged that C. auris is likely to be under reported due to the 
diagnostic limitations available in routine microbiology laboratories with C. auris 
often misidentified as other species or identified only to genus level (Snyder and 
Wright., 2019). According to Chowdhary et al (2017), the risk of a DM patient 
developing an infection from C. auris is similar to other Candida spp. at around 
18%. 
1.4.3 Aetiology  
Patients can become immunocompromised through a number of acquired and 
congenital mechanisms including DM (Zhou et al., 2018). Impaired immunity 
typically includes reduced immune surveillance, reduced capacity to clear 
pathogens and an increased susceptibility to infection (Nicholson., 2016). 
Commensal microbiota can be disturbed by the use of antibiotics, which, while 
targeting some bacterial species, allows other microbes to thrive due to reduced 
competition for resources (Langdon et al., 2016). In-dwelling medical devices, 
such as urinary catheters and central lines commonly used in intensive care units, 
and also provide a point of entry for microorganisms to invade the host as well as 
providing a substrate for them to proliferate (Raman et al., 2016). 
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1.4.4 Pathogenesis of C. auris 
Once a pathogen like C. auris has established colonisation, it has the various 
virulence factors which can cause damage to the host tissue. The host immune 
defences can detect infectious agents on the surface or within cells of the host 
mucosal epithelium and can activate the innate and adaptive immune response 
to clear pathogens (Caffrey and Obar., 2016). The immune system responds 
using an escalating manner to address threats posed by invading pathogens. The 
response includes symptoms associated with infection such as fever and 
increased white cell production. However, in the event of a systemic infection, an 
overzealous effort by the immune system to clear a pathogen can also lead to 
sepsis, a serious and often life-threatening complication of infection (WHO., 
2018). 
1.5 Pathogenic Candida 
1.5.1 How does Candida cause infection? 
Fungi are a diverse group of eukaryotic organisms that includes mushrooms, 
moulds and yeasts. Yeast typically grow as single cells and primarily multiply 
asexually occasionally via binary fission (fission yeast) as seen in the brewers’ 
yeast Schizosaccharomyces pombe whereby cells divide through mitosis similar 
to the cells of multicellular animals. Yeast cell division is most commonly via 
budding (budding yeast) where daughter cells (buds) emerge from the mother 
cell, enlarge and separate (Martin and Arkowitz, 2014). C. auris is an example of 
a budding yeast. The morphology of yeast varies amongst species, though they 
can exist as single cells (unicellular) or grow as filaments known as hyphae which 
can intertwine to form a mycelium.  There are an estimated 1.5-5.0 million fungal 
species, about 1500 are yeast species, most of which are harmless to humans 
9 
 
and only a few hundred are considered to be pathogenic (Köhler et al., 2015). 
Many are considered medically or commercially valuable and are used in the 
manufacture of a range of products including antibiotics, biodiesel, wine and 
bread. According to Brunke et al (2016), pathogenic fungi typically arise from two 
sources: environmental sources and host niches, with the majority coming from 
the environment. Brunke et al (2016) explain that environmental fungi are 
intermittently exposed to conditions similar to those found within human hosts 
which likely lead to evolutionary adaptations. Host microrelationships can be 
separated into two subgroups: obligate human pathogens and commensals. 
Obligate human pathogens can affect immunocompetent patients (patients with 
a healthy immune response) though the commensals usually colonise harmlessly 
in humans and are opportunistic pathogens which usually affect 
immunocompromised patients (Brunke et al., 2016). Candida spp. are 
opportunistic pathogens, the most common being Candida albicans (Borman et 
al., 2016).  Larkin et al (2017) have determined that C. auris has similar 
mechanisms of infection to C. albicans. C. albicans’ ability to colonise and invade 
host niches is largely due to its cell wall. The C. albicans’ cell wall contains 
specialised sets of proteins known as adhesins which mediate cell-cell 
adherence, and adherence between the host cell and abiotic surfaces, such as 
medical devices, which allow the C. albicans to colonise the skin and mucosa as 
well as materials such as urinary catheters (de Groot et al., 2015). Other 
specialised proteins known as invasins mediate induced endocytosis when they 
bind to host ligands triggering the host cell to engulf the yeast cell. Some yeasts 
such as C. albicans can alter their morphology and switch from yeast to hyphal 
cells, which can puncture the surface of the host cell and invade it in a process 
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known as active penetration (Mayer et al., 2013). The cell wall plays many roles 
in the virulence of Candida spp. Virulence describes the yeasts’ potential to cause 
disease in humans and Candida show many virulence factors or mechanisms to 
cause disease. Examples of these include the ability to secrete enzymes from 
within the cell wall, such as phospholipases and proteases (Larkin et al., 2017); 
which actively target attributes of the host cell membrane to facilitate the invasion 
of host cells 
1.5.2 Biofilms 
An important factor in the virulence of fungal pathogens is the ability to produce 
a biofilm. A biofilm is a consortium of microbes that can adhere to a surface such 
as epithelial cells or the surface of an in-dwelling medical device such as a urinary 
catheter and proliferate across the surface within an extracellular matrix (ECM) 
(Richardson et al., 2018). The ECM is comprised of water and extracellular 
polymeric substances (EPS) namely polysaccharides, proteins and DNA (Di 
Martino., 2018). The cells within the biofilm have a distinctive phenotype 
compared to their planktonic peers (free-floating cells) and a cell’s capacity to 
adhere to a surface to form a biofilm is mediated by regulatory adherence 
proteins. According to Gulati and Nobile (2016), the formation of a biofilm is 
largely influenced by the nature of the available surface, composition of 
environmental nutrients and quorum-sensing molecules. Quorum sensing is a 
method of microbial communication which utilises chemical signalling to regulate 
cell behaviours such as virulence and biofilm formation (Albuquerque and 
Casadevall., 2012). The development of a yeast biofilm begins with the seeding 
process. This starts with the initiation of a basal layer when a single yeast cell(s) 
begins to adhere to a solid surface such as an epithelial layer in vivo or a 
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microtitre plate in vitro. In C. albicans, adherence typically takes around 60-90 
minutes (Fox et al., 2015). The cells then begin to proliferate, usually through 
asexual processes, and the early biofilm begins to form. In some species, such 
as C. albicans, early stage filamentous growth can be observed which becomes 
more prominent as the biofilm matures (Gulati and Nobile., 2016). The mature 
biofilm contains layers of yeast cells and, depending on the species, hyphal 
(elongated thread like filaments) cells and pseudohyphal (formed of newly divided 
cells through budding) cells, which are surrounded by an ECM (Fox et al., 2015). 
A mature biofilm of C. albicans typically takes 24 hours to form. The final stage 
of biofilm development is the dispersal stage, where yeast cells are dispersed in 
order to seed new biofilm sites (Gulati and Nobile., 2016). The ability to form 
hyphae within a biofilm is considered important to provide structure and stability 
for the biofilm. This process is considered critical to the overall development and 
maintenance of the biofilm. The ECM is largely produced by the biofilm cells, 
though it also contains some environmental aggregates including some 
intracellular components of host cells, and the composition can vary depending 
upon the conditions (Fanning & Mitchell., 2012). A typical composition for a C. 
albicans biofilm is around 55% glycoproteins, approximately 25% carbohydrates, 
15% lipids and around 5% is nucleic acids.  It is worth noting that biofilms in vivo 
are not usually comprised of a single species and are typically a consortium of 
fungal and bacterial species (Alim et al., 2018). C. auris has not been reported to 
develop hyphae in its biofilm, though its biofilm is comprised of an ECM with a 
similar composition to C. albicans (Dominguez et al., 2019). Despite the absence 
of this critical biofilm component, Borman et al (2016) found the pathogenicity of 
non-aggregating strains comparable with C. albicans when they used the Galleria 
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mellonella infection model, a model which uses wax moth larvae as a host for 
infection. This contrasts with Larkin et al (2017) who found that C. auris showed 
weaker virulence in terms of biolfim formation and enzyme production than C. 
albicans and advise that the clinical significance of C. auris is largely due to its 
multidrug resistance. Biofilm formation in C. auris is also considered strain 
dependent with non-aggregating strains showing a greater propensity to form 
biofilms than aggregating strains (Singh et al., 2019). Another term for 
aggregation is flocculation which describes cell-cell adhesion where cells form 
clumps that settle out of suspension under the influence of gravity. Flocculation 
is a particularly sought-after quality in brewers’ yeasts like Saccharomyces 
cerevisiae which flocculate after the fermentation process is complete and settle 
to the bottom leaving the product clear of cells (Verstrepen & Klis., 2006).  
1.5.3 Phospholipase 
Phospholipases are a family of ubiquitous enzymes involved in a diverse range 
of biological processes. They are critical to cell survival and their actions are 
involved in cell membrane homeostasis, the digestion of nutrients, the formation 
of bioactive molecules, and they play a role in intracellular signalling pathways. 
Commonly, phospholipases also share the action of catalysing the hydrolysis of 
ester linkages in glycerophospholipids, the polar molecules which form the bilayer 
in cell membranes (Haas & Stanley., 2007). All phospholipases target 
phospholipids though they are categorised as A, B, C or D based on the specific 
bond they target (see Fig. 1.5.3.1). It is thought that phospholipases are 
employed by Candida spp. to facilitate invasion of host cells due to their ability to 





Cleavage sites of phospholipase A1, A2, C and D. Phospholipases are enzymes that hydrolyse 
phospholipids into fatty acids. Each class of phospholipase targets a specific bond within the 
phospholipid. 
1.5.4 Protease 
The term protease refers to enzymes whose function is to degrade proteins, 
though proteases can be divided into two subgroups: exopeptidase and 
endopeptidase (also called proteinases). Exopeptidase show specificity for small 
peptides as the substrate (Rao et al., 1998). Proteases are ubiquitous and play a 
role in DNA replication, transcription, cell proliferation and differentiation. Their 
action regulates the activity of many proteins and generates amino acids and 
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all areas of metabolism (López-Otín & Bond., 2008). Candida spp. produce many 
proteases and show proteolytic activity at a broad range of pH values which is 
likely to support survival in different host environments. Amongst the proteases 
produced by C. albicans are the secreted aspartyl proteases (SAP). There are 10 
forms that have be shown to have different optimum proteolytic activity in pH 
ranges from pH 2 up to pH 7 (Modrzewska et al., 2016). Candida spp. use 
protease to facilitate host invasion by degrading host mucins and extracellular 
membrane components such as the ECM and host endothelial cell tissues such 
as keratin and collagen. Candida spp. can also employ proteases to evade host 
immunity by degrading proteins involved in the immune response such as 
immunoglobulins, complement proteins and the proteins present in macrophages 
(Marcos., 2016). 
1.6 Diabetes and Candiduria 
Candida spp. can be recovered from urine and their presence can indicate 
colonisation of the urinary tract. Their presence in urine can be transient and 
asymptomatic, though the risk of infection is greater amongst 
immunocompromised patients (Falahati et al., 2016). DM is associated with 
immunological impairments and poorly controlled DM with glucosuria is 
associated with increased infection (Zhou et al., 2018). According to Falahati et 
al (2016), high blood glucose levels (hyperglycaemia) leave the gastrontestinal 
tract, urinary tract and mucous membranes vulnerable to infection. Mandal et al 
(2014) also state that high blood glucose reduces the effectiveness of anti-fungal 
agents. Their study found that glucose had a high affinity to bind with voriconazole 
thus decreasing its antifungal activity and indicating that poor glucose regulation 
in DM patients could result in a reduced response to anti-fungal treatment. 
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Mandal et al (2014) also suggest that the presence of glucose in urine may 
promote the growth of Candida, as glucose is a major carbon source for fungal 
species. In addition to a typically low pH, diabetic urine may provide a favourable 
medium for fungal propagation. Nyirjesy et al (2012) state that poor glycaemic 
control is associated with increased Candida species in urine, though it is not 
known whether this is a direct relationship whereby the excess glucose provides 
a carbon source for yeast species or if this is an indirect relationship as a result 
of the reduced immune response in the presence of high blood glucose in DM 
patients.  
1.7 Urine biochemistry 
The urine of DM patients typically has a lower pH (<5.5) than non-diabetic 
patients, though the mechanisms for this are not fully understood. Maalouf et al., 
(2010) considered a metabolic basis for low urine pH and found that the low pH 
persisted when factors such as diet, body size and age were controlled and 
concluded that the low urine pH was caused by a combination of greater net acid 
excretion and the impaired use of ammonia buffers in DM patients. A comparison 
of the urine of DM and non-DM patients within the study found there were 
significant differences in magnesium, ammonia, bicarbonate and citrate (Maalouf 
et al., 2010). The urine of diabetic patients is complex, though for the purposes 
of this investigation, only a change in pH and glucose will be considered though 
it is important to recognise that the other biochemical differences between DM 
and non-DM patient urine as discussed above which may impact upon the growth 
and virulence of C. auris.   
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1.8 Urine as a culture medium  
Microbial culture media is a solid (agar) or liquid (broth) which provides nutrients 
to support the growth of microbes. Culture media come in many forms, though 
they are broadly split into complex or defined media. Complex media contain a 
carbon source and a source of amino acids, though their exact composition is 
unknown. In a defined media, the exact chemical composition is known. For the 
purpose of this experiment, a defined synthetic urine (SU) medium was used. In 
order to support fungal growth, a culture medium must contain the following 
macroelements: carbon, hydrogen, oxygen, nitrogen, sulphur, calcium, iron, 
magnesium, phosphorus and potassium. Fungal species use these elements for 
numerous metabolic roles and in the synthesis of carbohydrates, proteins, lipids 
and nucleic acids. Fungal species also require growth factors in addition to some 
microelements (such as Mn, Zn, Co, Mo, Ni and Cu), which in vivo, form part of 
enzymes and cofactors (Basu et al., 2015). The SU was prepared to the 
specifications from Brooks (1997) and adapted to vary the pH and glucose levels. 
The SU contained yeast extract as a source of microelements and sources of all 
ten macroelements. Glucose provided the main carbon source, and urea and 
ammonia provided a source of nitrogen. In addition, peptone provided a source 
of proteins, peptides and amino acids (Abelovska et al., 2007).  
1.9 Measurement of growth 
This study will measure the growth of C auris using absorbance techniques. This 
technique has the advantage of being a fast way of ascertaining the bioload in a 
volume of liquid, however, it measures a pooled sample of cells and makes no 
distinction between live and dead cells (Nandy et al., 2015). To measure biofilm 
formation, biofilms will be stained with crystal violet which binds to cell proteins 
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and DNA staining them purple. The colour change can be observed by reading 
the absorbance at 600 nm when the biofilms are solubilised with a solvent such 
as glacial acetic acid (O’Toole., 2011). 
1.10 Assays to detect the enzymatic activity of C. auris 
To observe the phospholipase activity of C. auris in SU, an SU agar medium 
supplemented with egg yolk was used. The rationale for this method is that 
phospholipases degrade phospholipds in the egg yolk producing insoluble 
precipitates which can be observed as a halo around a colony of yeast cells 
indicating phospholipase activity (Aryal., 2019). To detect protease activity, an 
SU agar was supplemented with bovine serum albumin (BSA) which would be 
degraded by C. auris proteolytic enzymes. A stain was added to the agar to bind 
with proteins present in the media and the area around the colony of C. auris 
where protease activity had occurred would not absorb the stain (Ozkan et al., 
2005).  
1.11 C. auris strains 
This study used a non-aggregating strain (NCPF 8971) and an aggregating strain 
(NCPF 8977) acquired from PHE. The strains were selected as they had been 
used in a similar study of phospholipase, protease and biofilm production by 
Sherry et al (2017). The culture was managed to ensure that the same generation 
of the strains were used for all experiments. 
1.12 Experimental plan 
This study will focus on the growth and biofilm, phospholipase and protease 
production `of C. auris in a synthetic urine medium in the presence of varying 
concentrations of glucose and at different pH values. The glucose levels used in 
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the study were chosen based on those typically used in the diagnosis of 
glucosuria using semi-quantitative colorimetric assay or ‘dipstick.’ The glucose 
levels tested were 1, 2.5, 5. 10 and 20 mg/mL (Acon Labs., 2019). The pH levels 
used were 5.2, 5.6 and 6.3. A urine pH around pH 6 is considered normal, 
diabetics typically have a urine pH below pH 5.5. The pH values were selected 




2: Materials and Methods 
2.1 Preparation of media 
2.1.1 Preparation of agar 
Malt extract agar (Sigma-Aldrich, Gillingham, UK) was prepared according to the 
manufacturer’s instructions. 20 g of agar was dissolved in 400 mL of distilled 
water in a Duran (DURAN®, Mainz, Germany) bottle. The agar was then 
autoclaved using an electric bench top autoclave at 121 ⁰C for 15 minutes. The 
agar was tempered to 55 ⁰C before being poured into sterile petri dishes which 
were then stored in a refrigerator. 
2.1.2 Preparation of broth 
Malt extract both (MEB) (Sigma-Aldrich, Gillingham, UK) was prepared by adding 
4 g of MEB to 250 mL of distilled water. MEB was poured into universal bottles in 
10 mL aliquots or 25 mL was added to 250 mL conical flask which was sealed 
with a cotton wool bung and covered with four layers of aluminium foil. All 
preparations were autoclaved at 121 ⁰C for 15 minutes. 
2.2 Preparation of lyophilised culture 
The C. auris NCPF 8971 and NCPF 8977 were obtained from PHE. The capsules 
were broken using an appropriate tool and the paper strip containing the culture 
was added to 10 mL of sterile malt extract broth (Sigma-Aldrich, Gillingham, UK) 
in a universal bottle prepared according the manufacturer’s instructions. The 
cultures were allowed to rehydrate at room temperature for 3 minutes before a 
loop of the culture was streaked onto an MEA plate. Both the universal and the 
MEA plate were incubated without shaking at 37 ⁰C for 48 hours.  
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Primary cultures were stored in Brain Heart Infusion Broth (BHIB) (Sigma-Aldrich, 
Gillingham, UK), containing 20% (v/v) glycerol. Several colonies of a culture from 
the MEA plates were added to microcentrifuge tubes which were then frozen as 
the primary culture at -80 ⁰C. A further sub-culture of a colony of C. auris from the 
primary MEA plate was streaked onto another MEA plate which was incubated 
statically at 37 ⁰C for 48 hours. Several colonies of this sub-culture were added 
to 1.5 mL microcentrifuge tubes containing BHIB with 20% glycerol and they were 
frozen at -20 ⁰C. Each week, a sub-culture sample was defrosted and streaked 
onto a new plate. Once the sub-cultures were used, further sub-cultures were 
made from a frozen primary culture. 
2.3 Preparation of synthetic urine  
The synthetic urine media was prepared as shown in table 2.3.1 according to the 
method described by Brooks (1997), though the glucose and pH was adjusted 
according to the experimental design for this study. The media was prepared as 




Table 2.3.1 Components of synthetic urine media 
Component Quantity g/L 
Peptone (bacteriological) 1 
Yeast extract 0.005 
Lactic acid 0.1 
Citric acid 0.4 
Sodium bicarbonate 2.1 
Urea 10 
Uric acid 0.07 
Creatinine 0.8 
Calcium chloride.2H2O 0.37 
Sodium chloride 5.2 
Iron II sulphate.7H2O 0.0012 
Magnesium Sulphate.7H2O 0.49 
Sodium sulphate.10H2O 3.2 
Potassium dihydrogen phosphate 
 
0.95 
Di-potassium hydrogen phosphate 
 
1.2 
Ammonium chloride 1.3 
Distilled water Topped up to 100 mL for 10x concentrated stock which 
was diluted to make 1 L 
 
The components were added as shown in table 2.3.1 to a Duran (DURAN®, 
Mainz, Germany) bottle, their total weight was calculated as 27.21 g. 60 mL of 
distilled water was added. The pH was then adjusted. Due to the buffers used in 
the SU, hydrochloric acid (HCl) 10M was required to alter the pH. The solution 
was then topped up to 100 mL with distilled water. Following preparation of the 
10x stock, the mixture was separated into universal bottles. Glucose was added 
to each to give concentrations of between1-20 mg glucose/mL. A control stock 




2.4 Establishing growth of C. auris in synthetic urine 
The growth of both strains in SU was established by adding 1 mL of the control 
SU to a universal bottle and diluting with 9 mL of sterile distilled water. This was 
prepared in duplicate and each universal was inoculated with a loop of either C. 
auris NCPF 8971 or NCPF 8977. The process was repeated for each of the 
glucose concentrations. The bottles were incubated aerobically and without 
shaking for 18 hours at 37 ⁰C. Growth was confirmed visually after 18 hours in 
the control and all glucose concentrations. The process was repeated varying the 
pH between pH 5.2- 6.3 and growth was confirmed visually in the control at all 
pH levels and glucose concentrations.  
2.5 Overnight culture (OVC) 
2.5.1 OVC in MEB 
A 250 mL conical flask of MEB was prepared as above and inoculated with a loop 
of one colony of either C. auris NCPF 8971 or NCPF 8977. The flask was then 
incubated in an orbital shaker set at 180 rpm and 37 ⁰C for 18 hours. 
2.5.2 OVC in SU 
A 250 mL conical flask was used for each OVC. 22.5 mL of distilled water was 
added to a flask which was sealed with a cotton wool bung then covered with 
several layers of aluminium foil. The flasks were then autoclaved at 121 ⁰C for 20 
minutes. Following autoclaving, 2.5 mL of SU containing 1 mg glucose/mL was 
added to the flasks. The flask was then inoculated with a loop of one colony of 
the required strain of C. auris from an MEA plate. The flask was then incubated 
in an orbital shaker set at 180 rpm and 37 ⁰C for 18 hours. 
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2.6 Planktonic growth 
250 mL conical flasks were prepared as described above. To the autoclaved 
flasks, 2.5 mL of the required SU from the 10x concentrated stock was added. 
The flasks were inoculated with 1 mL of OVC in SU. Using a clean sterile tip, a 1 
mL sample was immediately taken and added to a cuvette and read at 600 nm 
using a spectrophotometer against a blank of diluted SU. The results were 
recorded, and the flasks were incubated in an orbital shaker set at 180 rpm and 
37 ⁰C for 24 hours. The flasks were sampled again. The initial absorbance was 
deducted from the final absorbance and recorded. 
2.5 Assays  
2.5.1 Biofilm crystal violet assay 
An OVC was centrifuged and diluted to a concentration to the equivalent of 107 
cfu/mL. This was an adaptation from the protocol by O’Toole (2011). Sterile 
filtered SU from the 10x concentrated stock at each glucose concentration was 
diluted with sterile distilled water with 1 part SU and 9 parts distilled water. Six 
wells of a 96 well plate were selected for each glucose concentration and an 
additional six wells for the positive control. To each well, 0.95 mL of the 
appropriate reconstituted SU was added. Each of the wells were then inoculated 
with 0.05 mL of the 107 cfu/mL culture. The plates were covered with an adhesive 
lid and incubated statically at 37 ⁰C for 24 hours. Following incubation, the 
supernatant was aspirated gently using a multipipette. 0.2 mL of distilled water 
was added to each well, the plate was agitated to dislodge loose cells and the 
water was then aspirated. This process was repeated three times. The biofilms 
were then stained with 0.125 mL of 0.1% (v/v) crystal violet solution. The plates 
were left to incubate at room temperature for 10-15 minutes before the crystal 
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violet was removed by aspiration and three rounds of washing with water. The 
plates were left to dry at room temperature for 18 hours. Once dry, 0.125 mL of 
30% (v/v) glacial acetic acid in distilled water was added to each well and left to 
incubate for 20 minutes at room temperature. The contents of each well were 
then transferred to a new plate using a multipipette. 0.125 mL of 30% (v/v) glacial 
acetic acid was added to an empty well to serve as a blank. The plates were then 
analysed using a Fluostar Omega optical density plate reader (BMG Labtech, 
Aylesbury, UK) at 550 nm. The absorbance of the blank well was deducted from 
the assay absorbance readings. 
2.5.2 Phospholipase assay 
The method was adapted from that described by Singh (2018). 2% (w/v) agar-
agar (Sigma-Aldrich, Gillingham, UK), 1% (w/v) bacteriological peptone (Lab-M, 
Heywood, UK), 5% (w/v) NaCl and 0.0006% (w/v) CaCl2 were dissolved in 
distilled water and autoclaved for 15 minutes at 121 ⁰C. The 10% (v/v) sterile egg 
yolk emulsion (Sigma-Aldrich, Gillingham, Germany) was prepared by 
centrifugation at 3000 rpm for 10 minutes in an Microcentaur (MSE, Heathfield, 
UK) centrifuge. The supernatant was removed and added to the molten agar 
together with 10% (v/v) sterile filtered synthetic urine (prepared as a 10x 
concentrated stock) at varying glucose concentrations. Inside a Class II Laminar 
Flow cabinet, the Duran (DURAN®, Mainz, Germany) bottle containing molten 
agar with added egg yolk and synthetic urine was placed in a beaker of hot water 
to keep molten until the pH was adjusted to either pH 5.2, 5.6 or 6.3 as required. 
The agar was then poured into sterile petri dishes and once set, stored in a 
refrigerator. An overnight culture was prepared as above. The cells were washed 
to remove MEB by adding 1 mL of the culture to the microcentrifuge tube and 
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centrifuging to pellet at 3000 rpm for 3 minutes. The supernatant was removed 
and 1 mL of sterile ¼ strength Ringer’s solution (Oxoid, Hampshire, UK) was 
added. The cells were resuspended using a Whirlmixer vortex mixer 
(Fisherbrand, Loughborough, UK) and centrifuged for a further 3 minutes at 3000 
rpm. The Ringer’s was removed, and a fresh 1 mL of sterile Ringer’s was added. 
The cells were resuspended using a vortex mixer. 0.1 mL of culture was added 
to a microcentrifuge tube containing 0.9 mL of Ringer’s to make a suspension 
equivalent to 108 cfu/mL. The agar plates were divided into four, and 0.01 mL of 
the culture was spotted onto the centre of each quarter of the agar. The plates 
were left to dry for around 20 minutes inside a Class II cabinet before they were 
sealed with parafilm and incubated statically upside down aerobically at 37 ⁰C for 
3 days. After three days, growth was confirmed visually at all pH and glucose 
levels. The phospholipase activity (Pz) was observed qualitatively by the 
presence of a precipitation zone around the colony (Larkin et al., 2017) and given 
a score of: 
- = no precipitation zone 
+ = precipitation zone 
2.5.3 Protease assay 
The method was adapted from a method described by Borst & Fluit (2003) and 
2% (w/v) agar-agar (Sigma-Aldrich), 0.5% (w/v) MgSO4, 1% (w/v) KH2PO4 were 
dissolved in distilled water and autoclaved for 15 minutes at 121 ⁰C. To the molten 
agar, 0.16% (w/v) BSA (Sigma-Aldrich, Gillingham, UK) (dissolved in water and 
filter sterilised) and 10% (v/v) sterile filtered synthetic urine (prepared as a 10x 
concentrated stock) was added. The pH was adjusted to either pH 5.2, 5.6 or 6.3 
26 
 
as required and the mixture was poured into petri dishes and stored as per the 
method used for the phospholipase assay preparation. An OVC was prepared in 
MEB and the cells washed above. The plates were quartered, and each quarter 
was inoculated with a 0.01 mL aliquot of cells at a concentration equivalent to 108 
cfu/mL. The plates were incubated for 5 days aerobically at 37 ⁰C without shaking. 
After 5 days, growth was confirmed visually at all pH and glucose levels. The 
plates were stained using an adapted method described by Vermelho et al 
(1996). The staining solution was prepared with 0.1% (w/v) Coomassie Brilliant 
Blue R250 (Life Science, California, United States), 10% (v/v) acetic acid and 
50% (v/v) methanol in distilled water. The plates were flooded with the staining 
solution and left to incubate at room temperature for 20 minutes. The plates were 
destained by flooding. The plates were flooded three times with a destaining 
solution prepared with 10% (v/v) acetic acid and 40% (v/v) methanol in distilled 
water and incubated at 37 ⁰C for 20 minutes and finally with distilled water for a 
further 20 minutes at 37 ⁰C. Following destaining the protease activity (Prz) was 
observed qualitatively by the presence of a clear zone around the colony and 
given a score of:  
- = no clear zone 
+ = clear zone 
2.6 Statistical analysis 
Normality testing using a histogram, Q-Q plot and Shapiro-Wilks was performed 
to confirm the data are normally distributed. One-way ANOVA was used to 
compare the means followed by Tukey’s post-hoc analysis where a result was 




C. auris is an emerging fungal pathogen that was first identified in 2009. The 
pathogen is a cause for concern for world health organisations as it has shown 
resistance to antifungal treatments from each class of drugs and to routine 
cleaning regimes. Those most at risk are patients with impaired immunity, such 
as patients with DM, and those with an indwelling medical device, such as a 
urinary catheter, in situ. The study exposed an aggregating and non-aggregating 
strain of C. auris to conditions mimicking those found in the urine of patients with 
diabetes mellitus to observe if there was a difference in the production of biofilms, 
phospholipase and protease when the pH and glucose levels were altered. 
 
3.1 Planktonic growth  
The cells were grown over 24 hours by the method demonstrated in 2.6. Flasks 
were prepared (n=3) with 1-20 mg glucose/mL and a control without glucose at 
pH 5.2, 5.6 and 6.3. In the non-aggregating strain (NCPF 8971), at pH 5.2, the 
growth increases with the glucose concentration. At pH 5.6 (see Fig. 3.1.2), the 
growth increases with glucose, though the mean absorbance is significantly lower 
overall than pH 5.2. At pH 6.3 (see Fig 3.1.3), the growth appears to plateau after 






















Flasks were prepared (n=3) for the aggregating strain (NCPF 8977) using the 
same method described in 2.6. At pH 5.2 (see Fig. 3;1;4), the growth is similar to 
the growth seen in the non-aggregating (NCPF 8971) strain. At pH 5.6 (see Fig. 
3.1.5), the growth is comparable to the non-aggregating strain. At pH 6.3 (see 
Fig. 3.1.6), there was no measurable growth was seen in the control group. At 20 



















3.2 Statistical analysis for planktonic growth in SU 
 
Analysis for the non-aggregating (NCPF 8971) strain and aggregating (NCPF 
8977) strain. A one-way ANOVA was performed and demonstrated a significant 
difference and Tukey’s post-hoc analysis revealed significant differences. Table 
3.2.1 shows growth of the non-aggregating (NCPF 8971) strain (n=3) and shows 
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a significant difference from the control in 2.5-20 mg glucose/mL at all pH levels. 
Table 3.2.2 shows growth of the aggregating (NCPF 8977) strain (n=3) and 
shows growth was significantly different from the control in all glucose 
concentrations at pH 5.2 and pH 5.6, and in 2.5-20 mg/mL at pH 6.3. 
 
 
Table 3.2.1 Statistical analysis for planktonic growth in the non-aggregating 
(NCPF 8971) strain 
 





at 600 nm p value 
Mean 
absorbance 
at 600 nm p value 
Mean 
absorbance 
at 600 nm p value 
Control 0.860 - 1.046 - 0.980 - 
1 3.200 0.057 2.062 0.209 1.730 0.975 
2.5 5.840 < 0.0001 3.316 0.001 5.000 0.022 
5 9.700 < 0.0001 4.792 < 0.0001 9.010 < 0.0001 
10 14.130 < 0.0001 8.519 < 0.0001 8.850 < 0.0001 
20 20.240 < 0.0001 13.393 < 0.0001 9.050 < 0.0001 
 
Table 3.2.2 Statistical analysis for planktonic growth in the aggregating 
(NCPF 8977) strain 
 





at 600 nm p value 
Mean 
absorbance 
at 600 nm p value 
Mean 
absorbance 
at 600 nm p value 
Control 0.980 - 0.841 - 0.000 - 
1 3.150 < 0.0001 2.346 0.018 1.470 0.448 
2.5 4.860 < 0.0001 3.850 < 0.0001 4.660 0.001 
5 8.730 < 0.0001 6.109 < 0.0001 6.190 < 0.0001 
10 13.940 < 0.0001 10.015 < 0.0001 9.860 < 0.0001 
20 19.910 < 0.0001 14.180 < 0.0001 20.550 < 0.0001 
 
The SU media was shown to promote growth of planktonic cells (cells which 
remain in suspension and do not adhere to a surface) in both strains of C. auris. 
An increase in growth was generally seen in line with increasing glucose 
concentrations, although the absorbance showed some variation with respect to 
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a change in pH. The non-aggregating strain (NCPF 8971) saw the highest mean 
absorbance at pH 5.2 with the growth increasing significantly (p=<0.0001) as the 
glucose concentration increased. The same pattern of growth could be seen at 
pH 5.6, though the absorbance was much lower with a mean absorbance of 
13.393 at 20 mg glucose/mL at pH 5.6 compared with an absorbance of 20.240 
at pH 5.2 at the same glucose concentration. At pH 6.3, the mean absorbance 
was almost double that with 2.5 mg glucose/mL supplementation than at pH 5.2 
and 5.6 and growth at 5 mg glucose/mL was similar to pH 5.2, though almost 
double the growth seen at pH 5.6. The non-aggregating strain (NCPF 8971), 
showed comparable growth to the aggregating strain (NCPF 8977) at pH 5.2 and 
pH 5.6; however, some differences can be observed at pH 6.3 which showed no 
measurable growth in the control group but showed growth in the 20 mg/mL 
comparable to the growth seen at pH 5.2. The key findings showed that there 
was no significant difference in the control groups at pH 5.2 or pH 5.6, though SU 
inoculated with the tested strains at pH 5.6 produced significantly (p= <0.0001-
0.05) less growth than pH 5.2 once glucose was added at all concentrations 
(except 2.5 mg/mL at pH 5.6 which showed wide variability amongst the results). 
 
3.3 Determination of biofilm formation 
Biofilm formation was determined by the method described in section 2.5.1. The 
tested strains were grown in SU media (n=6) with varying glucose and pH and 
analysed after 24 hours. Fig. 3.3.1 and Fig. 3.3.2 show that though there was a 
difference in biofilm formation between the two tested strains, there was no 















When viewed under an inverted light microscope at x400, the biofilm cells stained 
with 0.1% crystal violet (as per the method described in section 2.5.1) appeared 










A. Control without glucose. Cells appear elongated or oval shaped and are joined in pairs 
or short chains. B. With 1 mg glucose/mL, cells appear larger and rounder than the control 
group and contains mostly single cells. C. With 2.5 mg glucose/mL, many budding cells 
can be seen. All cells were observed using an inverted light microscope at x400. 
 
Figure 3.3.4 Images of aggregating (NCPF 8977) biofilm 
 
 
A. Control without glucose, very few single cells can be seen with most cells seen in pairs 
or groups. Budding cells can be seen. B. with 1 mg glucose/mL, few single cells can be 
seen. C. with 2.5 mg glucose/mL, some single cells can be observed in addition to large 









The crystal violet assay has shown that, overall, the glucose concentration and 
pH level did not appear to have a great effect upon biofilm production after 24 
hours (Figure 1). Some differences could be seen when in the non-aggregating 
strain (NCPF 8971), particularly at pH 5.6 where the mean biomass was lower at 
some glucose concentrations (5, 10 and 20 mg/mL) than in pH 5.2 and pH 6.3. 
There are some notable differences in the morphology of the biofilm cells in 
response to the glucose concentration; in the control group, the non-aggregating 
strain (NCPF 8971) appeared to form chains (Fig. 3.3.3. A), though there are 
mostly single cells present at 1 mg glucose/mL (Fig 3.3.3. B). Very few single 
cells can be seen in the aggregating strain (NCPF 8977) in the presence or 
absence of glucose (Fig. 3.3.4). 
 
3.4 Determination of phospholipase activity 
The phospholipase assay was prepared using the method described in section 
2.5.2. The tested strains were inoculated onto the SU agar supplemented with 
egg yolk at varying glucose concentrations and pH levels (n=4). Qualitative 
analysis was used to determine if phospholipase activity was positive or negative 
(see Table 3.4.1) by a visually examining the colonies for the presence or 





Table 3.4.1 The phospholipase activity of the tested strains 


















Control + + + + + - 
1 - + + + + - 
2.5 - + + + + - 
5 - - + - + - 
10 - - + - + - 
20 - - + - + - 
 
 
Figure 3.4.2 Image of a colony positive for phospholipase 
 
  
Image shows a colony of C. auris NCPF 8971 positive for phospholipase activity (Pz). The colony 
was grown on an SU agar plate without glucose and supplemented with egg yolk at pH 5.6. 
 
At pH 5.6, the aggregating strain (NCPF 8977) showed similar phospholipase 
activity to pH 5.2, whereas the non-aggregating strain (NCPF 8971) showed 
activity at all concentrations of glucose including the control. At pH 6.3, the non-
aggregating strain (NCPF 8971) again showed phospholipase activity at each 






control and the groups with glucose. The aggregating strain (NCPF 8977) showed 
no activity at pH 6.3. 
3.5 Determination of protease activity 
The protease assay was prepared using the method described in section 2.5.3. 
The tested strains were inoculated onto the SU agar supplemented with BSA at 
varying glucose concentrations and pH levels (n=4). As per the phospholipase 
assay, qualitative analysis was used to determine if protease activity was positive 
or negative (see Table 3.5.1) by a visually examining the colonies for the 
presence or absence of a clear zone (see Fig. 3.5.2) following staining as per the 
method described in section 2.5.3. 
 
Table 3.5.1 The protease activity of the tested strains 
 
 























Control - - - + - + 
1 - - + + + + 
2.5 - + + + + - 
5 - + + + + - 
10 - + - - + - 
20 + - - - + - 
 
The protease activity of non-aggregating (NCPF 8971) and aggregating (NCPF 8977) 
strains of C. auris. The cells were grown on SU agar supplemented with BSA at varying pH 
levels and glucose concentrations and incubated aerobically at 37 ⁰C for 5 days. A negative or 









The image shows a colony of C. auris NCPF 8971 positive for proteinase activity (Prz). The colony 
was grown on an SU agar plate without glucose and supplemented with BSA at pH 5.6. The 
colony has been stained with Coomassie Brilliant Blue R250 and a destaining solution was used 
to reveal a clear zone around the colony. 
 
At pH 5.2, the non-aggregating strain (NCPF 8971) only showed proteolytic 
activity at the highest glucose concentration whereas the aggregating strain 
(NCPF 8977) showed proteolytic activity between 2.5 and 10 mg/mL. At pH 5.6, 
the non-aggregating strain (NCPF 8971) showed proteolytic activity between 1 
and 5 mg/mL and the aggregating strain (NCPF 8977) demonstrated proteolytic 
activity between the control group and 5 mg/mL. At pH 6.3, the non-aggregating 
strain (NCPF 8971) showed proteolytic activity in all glucose concentrations 
except the control group and the aggregating strain (NCPF 8977) showed activity 
in only the control group and 1 mg/mL. The non-aggregating strain (NCPF 8971) 
showed no proteolytic activity in the groups without glucose at any pH, whereas 
the aggregating strain (NCPF 8977) showed proteolytic activity in the control 
group at pH 5.6 and pH 6.3, though the activity was arrested as the glucose 
concentration increased. 




This study aimed to investigate the role of pH and glucose in biofilm, 
phospholipase and protease production in C. auris. C. auris is an emerging 
species of Candida that was first isolated in 2009. It has been identified as a 
growing concern amongst health organisations worldwide because it is highly 
resistant to multiple drugs from all three antifungal categories and routine 
cleaning protocols. Those most at risk are severely immunocompromised 
patients with indwelling medical devices such as an in situ urinary catheter. 
Patients with diabetes have been identified as at risk due to their poor immunity 
and associated co-morbidities. This study aimed to determine whether a high 
glucose concentration and low pH associated with the urine of patients with 
diabetes increased the virulence of C. auris, thus increasing the risk of invasive 
infections. The study used a synthetic urine medium to mimic the conditions found 
in the urine of DM patients. The SU medium was shown to promote growth of 
planktonic cells of the two strains of C. auris with a low pH and high glucose 
concentration which provided good growth conditions. According to Ries et al., 
2018, glucose is an ideal carbon source as pathogenic fungi have a demonstrable 
preference for carbon sources that can be metabolised quickly and provide the 
energy required for growth and colonization in a host niche.  
4.1 Planktonic growth 
Larkin et al., (2017) found that C. auris had a similar planktonic growth profile to 
C. albicans when grown in RPMI (Roswell Park Memorial Institute) 1640 medium. 
In this study, there was some difference observed in the behaviour of the two 
strains with respect to both glucose and pH. After 5 mg glucose/mL, growth 
appeared to plateau in pH 6.3, though the variability amongst the 10 and 20 
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mg/mL groups questions the confidence in this result. The findings by Larkin et 
al., (2017) suggest that the non-aggregating strain (NCPF 8971) should have a 
similar pattern of growth to the aggregating strain (NCPF 8977) and the plateau 
seen in pH 6.3 may be an experimental error as indicated by the variation of 
results within the group.  
4.2 Biofilm production 
In this study, though not significant, a decline was also seen in the biofilm assay 
where there appeared to be a decline in biomass after 5 mg glucose/mL at pH 
6.3; however, again, the variability amongst the results in this study means that 
this cannot be commented upon with any certainty. It is worth noting that Larkin 
et al., (2017) did not alter the glucose concentration of the RPMI 1640 medium 
they used, which had a concentration of 2 mg glucose/mL which is lower than 
most of the concentrations used in this study. Larkin et al., (2017) also did not 
investigate the effect of pH on growth and if no adjustments were made to RPMI 
1640, when prepared according to the manufacturer’s instructions, the media 
would have a pH of 7-7.6 which is higher than the pH levels used in this study. 
Studies into the C. albicans have found that it has adapted mechanisms to thrive 
at a range of acidic pH levels such as those found in the vagina (pH 4-5) and oral 
mucosa (pH 6), it has also been observed to grow in pH levels as low as 2 such 
as those found in the stomach and as high as pH 10 (Sherrington et al., 2017).  
4.2.1 Biofilm production in response to environment 
Yeast cells like C. albicans prefer a slightly acidic pH which is largely driven by 
nutrient uptake. According to Polke et al., (2015) micronutrients such as iron are 
soluble at an acidic pH, and the stability and functionality of fungal proteins are 
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negatively affected by a raised pH. However, C. albicans has adapted 
mechanisms to respond to environmental pH where signalling pathways drive 
downstream responses allowing the species to survive at an alkaline pH (Polke 
et al., 2015). This study used 3 acidic pH levels which provide a favourable 
environment for C. albicans, though the ranges are much narrower than those 
seen in similar studies which have compared much more acidic and alkaline pH 
levels. This has allowed the opportunity to see alterations in growth a slight 
change in the pH can cause such as the difference seen between pH 5.2 and pH 
5.6. A normal urine pH is considered to be around 6.0 to 7.5 (Maalouf et al., 
2010). The results have shown that, overall, glucose and pH did not appear to 
have a great effect upon biofilm production after 24 hours. Some differences 
could be seen in the non-aggregating strain (NCPF 8971), particularly at pH 5.6 
where the mean biomass was significantly lower at some glucose concentrations 
(5- 20 mg/mL) than in pH 5.2 and pH 6.3. The low variation in the biofilm formation 
in the tested strains across the range of pH and glucose levels when compared 
to growth of planktonic cells could indicate that C. auris biofilms have an ability to 
tolerate and thrive in a wide range of conditions. Indeed, Modrzewska et al (2016) 
found that protease enzymes, for example, had optimum activity in varying 
conditions. Whilst the results did not show a statistically significant difference 
between the biofilm formation in the two strains, the consistently higher mean 
across all results may indicate that the non-aggregating strain (NCPF 8971) had 
a greater propensity for biofilm formation than the aggregating strain (NCPF 
8977) as demonstrated by Sherry et al (2017). This contradicts Oh et al (2011) 
who tested 15 strains of C. auris and found they did not produce a biofilm. 
However, Oh et al (2011) used Sabouraud Dextrose Broth (SDB) with 8% glucose 
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which is four-fold greater than the highest glucose concentration used in this 
study. The study by Oh et al (2011) does not indicate whether the pH was 
adjusted from a pH of 5.6 when prepared according to the manufacturer’s 
instructions. In this study, biofilm formation at pH 5.6 has the lowest biofilm 
formation overall, and the lowest for the non-aggregating strain (see Fig. 3.3.2). 
This observation is more pronounced as the glucose concentration was 
increased which indicates that high glucose and a pH of 5.6 may not provide ideal 
conditions for biofilm formation. In planktonic growth at pH 5.6, C. auris showed 
the lowest growth after 24 hours. Sherry et al (2017) also investigated NCPF 8971 
and NCPF 8977 and used RPMI-1640 medium which has 2 mg/mL of glucose 
and found that both strains produced a biofilm. The non-aggregating strain (NCPF 
8971) produced more biomass than the aggregating strain (NCPF 8977), which 
is consistent with the observations of this study.  
4.2.3 Biofilm production in response to glucose 
In a study on biofilm formation of Candida species other than C. albicans, Ng et 
al (2016) found that low glucose environments (0.1-2 mg/mL) promoted Candida 
glabrata biofilm formation significantly more (p= <0.05) than high glucose 
environments (10-20 mg/mL). They found that the optimal glucose concentration 
for biofilm production in C. glabrata was 2 mg/mL. A study of Candida parapsilosis 
by Pereira et al (2015) found that glucose enhanced biofilm formation, particularly 
at high glucose concentrations of 10% (100 mg/mL), though this was strain 
dependent with one of the tested strains showing no significant difference in 
biofilm formation across all tested glucose concentrations. Further studies of 
biofilms in C. albicans and C. glabrata by Hosida et al (2018) found that biofilm 
formation varied dependent on the strain, media, glucose concentration and 
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whether biofilms were composed of single or mixed species. As a single biofilm, 
Hosida et al (2018) saw that C. glabrata demonstrated no significant change in 
biofilm formation in RPMI 1640 regardless of the glucose concentration, though 
there was a significant difference when they used SDB supplemented with 1 mg 
glucose/mL rather than no glucose or 5 mg glucose/mL. This study is limited as 
it only used synthetic urine as a culture media and differences in biofilm formation 
may have been seen if other types of media had been tested. 
4.2.4 Biofilm production in synthetic urine  
A study by Uppuluri et al (2009) compared C. albicans biofilms grown in a SU 
media to those grown in RPMI 1640 and found that after 24 hours there was 
significantly less biomass in the SU group and that the SU biofilms were less 
mature than those grown in RPMI 1640. Studies of C. auris by Larkin et al (2017) 
and Borman et al (2016) have defined a clear difference between strains and 
identified them as aggregating and non-aggregating strains.  
4.3 C. auris virulence 
Larkin et al (2017) have noted that the aggregating strain (NCPF 8977) appears 
to produce less enzymatic activity and biofilm formation than the non-aggregating 
strain. Overall, C. auris appeared less virulent than C. albicans by producing 
around 50% less biomass in its biofilm and only 1 of the 16 isolates they tested 
had phospholipase activity comparable to C. albicans. They advise that C. auris’ 
multi-resistance to antifungal treatments has come at a cost to its virulence which 
is demonstrable by C. auris causing infection in severely immunocompromised 
patients rather than immunocompetent patients like C. albicans (Larkin et al., 
2017). However, its multi-resistance to antifungal drugs is concerning as it makes 
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infections difficult to treat and its resistance to routine cleaning means that 
outbreaks are more likely to spread (ECDC., 2018). In terms of planktonic and 
biofilm growth, this study has found no clear differences between strains. 
However, clear differences can be seen when viewing biofilm images (see Fig. 
3.3.3 and Fig. 3.3.4). The non-aggregating strain (NCPF 8971) consists of mostly 
single cells when in the presence of glucose, though it formed short chains in the 
control group. Its biofilm appeared to grow across the surface of the substrate 
rather upwards in a 3D structure. The aggregating strain (NCPF 8977) consists 
of few single cells, with most cells in pairs or groups. It appeared to have a 3D 
structure to its biofilm. It could also be noted that many cells in the images had 
not taken up the CV stain which could have impacted the measurement of the 
biomass. Larkin et al (2017) also observed the presence of oval, budding cells 
either as single cells or aggregates in a strain dependent manner.  
4.4 Aggregating vs non-aggregating 
Though not empirically tested, it was observed in this study that the aggregating 
strain (NCPF 8977) required continuous shaking to keep the cells suspended 
indicating that cells are settling as seen in species like Saccharomyces cerevisiae 
as discussed above. However, Borman et al (2016) suggests that the aggregation 
seen in the aggregating strain (NCPF 8977) is likely to be the result of budding 
cells not relinquishing their daughter cells rather than flocculation. When 
examining the images taken in this study, few single cells can be seen in the 
aggregating strain (NCPF 8977), though there are many pairs and groups (see 
Fig. 3.3.4).  
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A study by Verstrepen and Klis (2006) investigated flocculation of 
Saccharomyces cerevisiae and found that flocculating strains settled at the 
bottom of a liquid medium after 5 minutes, non-flocculating strains remained 
suspended, whereas a third strain formed microclumps of 2-10 cells resulting in 
some sedimentation. Though not as dramatic as the flocculating strain seen in 
the study by  Verstrepen and Klis (2006), the cells of the aggregating strain 
(NCPF 8977) used in this study did not remain suspended like that of the non-
aggregating strain (NCPF 8971) indicating that it could be flocculation contrary to 
the findings of Borman et al (2016). Borman et al (2016) also stated that they 
were unable to disrupt the aggregates despite intense vortex mixing. This was 
also an observation noticed in this study as a difference between the two strains 
when attempting to resuspend cells with a vortex mixer following centrifugation 
which took much longer to achieve in the aggregating strain. 
4.5 Phospholipase activity 
Generally low phospholipase activity was seen in both strains though this 
appeared to vary according to pH and glucose concentration. This is consistent 
with the findings by Larkin et al (2017) who tested 16 C. auris isolates and found 
they had limited or no phospholipase activity. Kumar et al (2015) tested a clinical 
isolate from a 28-year-old female and found that it had high phospholipase 
activity. However, Kumar et al (2015) gives no indication of the pH used in the 
case study and Larkin et al (2017) did not investigate multiple glucose 
concentrations and pH levels as seen in this study. Samaranayake et al (1984) 
studied the effect of pH and glucose on C. albicans isolates and found that the 
lower pH of 3.6 produced more phospholipase activity in the Pz positive strains 
than at pH 4.4, and they found no phospholipase activity at pH 5.1 or 6.3. They 
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also found that increasing concentrations of glucose, sucrose and galactose 
appeared to suppress phospholipase activity. Interestingly, Samaranayake et al 
(1984) found sucrose and galactose showed reduced phospholipase activity as 
the concentration increased, whereas glucose saw similar results at 50 and 100 
mM (same concentrations as 10 and 20 mg/mL), and activity diminished once 
further glucose was added. In this study, at pH 5.2, the non-aggregating strain 
(NCPF 8971) showed phospholipase activity in the control group, though it 
showed no activity once glucose was added. The aggregating (NCPF 8977) strain 
showed phospholipase activity in the presence of up to 2.5 mg/mL of glucose, 
but no activity at higher concentrations. In line with the findings by Samaranayake 
et al (1984) for C. albicans, the aggregating strain (NCPF 8977) also showed no 
phospholipase activity at pH 6.3, though activity was seen at all glucose 
concentrations in the non-aggregating strain (NCPF 8971) at the same pH. There 
was variability within the groups and phospholipase activity did not appear to 
increase in line with increased glucose concentration. However, Samaranayake 
et al (1984) reported that increasing the glucose concentration diminished the 
‘halo’ or zone of activity around the colony, which may have affected their ability 
to accurately measure the Pz zones.  Sanita et al (2013) tested the phospholipase 
and protease activity of C. albicans isolates from patients with oral candidiasis 
and healthy patients from groups of patients with or without diabetes. Although 
they found that phospholipase production was greater in isolates taken from 
patients with candidiasis, they found no significant difference between 
phospholipase activity in diabetic and non-diabetic patients. However, all strains 
were tested on the same egg yolk medium with 30 mg/ml of glucose to determine 
if patients with candidiasis harboured more virulent strains of C. albicans. 
47 
 
However, it is worth noting that in this study, the strains vary their enzymatic 
activity according to the pH and glucose levels of the culture media regardless of 
their source environment. The 30 mg/mL used in the study by Sanita et al (2013) 
is much higher than is typically seen in vivo (normal fasting blood glucose is 
typically 0.6 – 1.0 mg/mL (Güemes et al., 2015)), and as demonstrated by 
Samaranayake et al (1983), may have suppressed the phospholipase activity. 
Importantly, Sanita et al (2013) investigated whether the diminished 
phospholipase halo in the presence of glucose was due to inactivity of 
phospholipase or due to poor visualisation of the halo and they added potassium 
tellurite to the egg yolk medium to improve visualisation by staining the colonies 
black. Future studies investigating phospholipase in the presence of glucose 
might consider this as a method to improve visualisation. In this study, a 
qualitative measure was used to record enzymatic activity due to the relatively 
small zones around the colonies which were difficult to measure accurately, and 
a quantitative measure could be employed if visualisation was improved. Sanita 
et al (2013) also reported that visualisation of enzymatic activity was improved 
when colonies were incubated for 7 days, and this study only incubated 
phospholipase and proteinase plates for 3 days and 5 days respectively. 
4.6 Protease activity 
The aggregating strain (NCPF 8977) appeared to have less proteolytic activity in 
the presence of glucose as the pH increased. The opposite appeared to be the 
case for the non-aggregating strain (NCPF 8971) which showed more activity as 
the pH increased (see Fig. 3.5.1). In all cases, only weak protease activity was 
observed and there was no significant difference between the groups where 
activity was shown. Kumar et al (2015) found that their C. auris isolates produced 
48 
 
phospholipase and protease with zones that could be measured quantitively. This 
study produced very small precipitation and clear zones around the colony which 
were difficult to measure accurately and could be explained by the fact that this 
study substituted a typical rich media for SU media which has been shown to 
produce less growth and biofilms (Uppuluri et al., 2009). Kumar et al (2015) state 
they used a BSA agar in their experiment though the study does not specify the 
glucose concentration or the pH which has been shown to have some impact on 
the production of phospholipases and proteases. The media components can 
also impact on activity; Karkowska-Kuleta et al (2019) looked at the surface 
proteins of three non-albicans Candida spp. grown in six different media and 
found the lowest presence of surface proteins in C. tropicalis grown in a SU 
media. Interestingly, they found a wide variation of proteins across all media for 
all species used in the study. Though Sanita et al (2013) compared strains from 
diabetic and non-diabetic patients when they looked at phospholipase and 
protease activity, they did not consider the availability of a carbon source in vivo 
as a parameter and the diabetic patients included in the study had well-controlled 
type II diabetes. This study has considered glucose as a potential factor in the 
proteolytic activity of the two strains. The study by Sanita et al (2013) also 
investigated C. albicans which is used as a model for comparison in this study 
due to the lack of data available on C. auris, though it may offer a distinct virulence 
profile. Buu et al (2014) also studied C. albicans and found that lower rather than 
higher glucose concentrations were more potent in activating some SAP proteins 
and found higher concentrations of the protein Sap5 in the media containing the 
equivalent of 1 mg/mL of glucose than in the media containing the equivalent of 
20 mg glucose/mL. They also found that the higher concentration of 20 mg/mL 
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appeared to delay or have a suppressive effect on Sap5 production. In the 
aggregating strain, activity was generally seen at the lower glucose 
concentrations, though this varied according to pH. The study by Buu et al (2014) 
did not consider the pH of the culture media. As discussed above, there may have 
been some discrepancy when visualising protease activity. Sanita et al (2013) 
found visualisation was improved when the protease assay plates were incubated 
for 7 days rather than the shorter periods in other literature such as the 5 days 
used in this study, which could be considered in future studies. 
4.7 Limitations and future improvements 
There were a number of key areas highlighted by the study that could have 
clinical relevance. In terms of biofilm, the was no real difference in biofilm 
formation with respect to the concentration of glucose or the pH, though variability 
in the results indicate that more repetition is required to provide a more confident 
conclusion. However, the results could also suggest that C. auris biofilms can 
tolerate a range of pH and glucose conditions. With respect to phospholipase and 
protease, glucose concentration and pH did appear to be relevant. A normal urine 
pH of 6.3 may offer some protection from the aggregating strain (NCPF 8977) 
which showed no activity from either phospholipase or protease, though a 
reduction in the pH could mean the patient is at risk even if there is little to no 
glucose present. A high glucose concentration could provide some protection 
from the aggregating strain (NCPF 8977), though there are accompanying co-
morbidities associated with high glucosuria. A low urine pH may provide some 
measure of protection from this particular non-aggregating strain (NCPF 8971) in 
terms of protease, though a mid-normal pH could put a patient at risk. The wide 
variation of activity across pH levels and glucose concentrations indicate that 
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there is some mechanism by which C. auris can adapt to respond to its 
environment and invade the host niche by responding to pH and nutritional 
requirements. Certainly, Modrzewska et al (2016), have determined that there 
are SAP proteins which function at a range of pH levels.  In terms of treatment, 
these findings can give no indication if a patient with poorly controlled DMII is at 
greater risk of infection by C. auris than a patient with well-controlled DMII as the 
response to pH and glucose concentration appear to be strain dependent. 
However, as discussed above, there is evidence to suggest that high blood 
glucose has a detrimental effect upon immune response and patients with poorly 
controlled DMII may be at greater risk of infection regardless of the level of 
glucose excreted or the pH of the urine (Zaccardi et al 2015). By providing 
nutrients and conditions similar to those found in vivo, SU is a useful media to 
mimic the environments that pathogenic yeast isolates are found in (Uppuluri et 
al., 2009). However, there were some difficulties ensuring an even mixture in the 
SU due to the number of insoluble components, such as calcium carbonate in the 
SU, and this was particularly evident in the highest pH of 6.3. Goss et al (2007) 
studied the role of pH in the solubility of metals including calcium carbonate and 
found that it became soluble below pH 4.5. The pH levels used in this study were 
higher, meaning that some components were insoluble. It was necessary to 
separate the mixture so that the correct amount of glucose could be added before 
it was filter sterilised. If the mixture was not properly mixed, then this resulted in 
the remaining stock SU having a higher proportion of insoluble precipitates which 
also raised the pH. This was managed by using a magnetic stirrer to mix the 
solution thoroughly while a syringe was used to draw the required amount. 
Despite this, the pH could differ between the solutions by as much as +/- 0.1, 
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though any change in pH was corrected, the difference suggests there could be 
variation in the components of the SU media. Variation in the components could 
also arise from using syringe filtration as a method to sterilise the media. 
According to Pillai et al (2016) syringe filters provide a means to remove bacteria 
and any undissolved particles. Removing undissolved particles could alter the 
biochemical profile of the formulation. Autoclaving was not explored as a method 
of sterilisation because other studies using synthetic urine only used filtration, 
furthermore insoluble particles would need to be removed to ensure that an 
accurate absorbance was achieved. Measures to overcome this could include 
using a commercially available SU or by using pooled clinical samples, though 
there would still need to be adjustments made to the pH and glucose 
concentration. Though not tested empirically, several observations have been 
made regarding the difference in behaviour between the two strains which, are of 
interest. This has also meant that some adjustments have been made to account 
for them. There have been some observations made with respect to the longevity 
and robustness of the two strains. It has been noticed that an OVC could not be 
prepared from an agar plate of the aggregating strain (NCPF 8977) that has been 
stored in the refrigerator for more than three weeks, whereas cells can be cultured 
from an agar plate of the non-aggregating strain (NCPF 8971) of the same age. 
It has also been observed that there was no measurable growth in the control 
group at pH 6.3 after 24 hours when cultured in SU broth. Though this broth 
lacked the addition of glucose as the main carbon source, minimal growth was 
seen at pH 5.2 and pH 5.6 and a biofilm grew in the control group at pH 6.3.  As 
discussed, the aggregating strain (NCPF 8977) cells appeared to settle, and cells 
were required to be vortex mixed regularly throughout the experiment to keep the 
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cells suspended. Despite regular mixing, there could have been minor differences 
in the concentration of cells used in the experiments. 
5: Conclusion 
In conclusion, biofilm formation was not significantly impacted by changes in pH 
and glucose. There were interactions between pH and glucose where 
phospholipase and protease activity varied depending on the pH level and/or the 
glucose concentration, though more studies need to be conducted to determine 
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